A Phase I, Open-Label Study to Determine the Effect of Repeat Dosing of Trametinib on the Pharmacokinetics of a Combined Oral Contraceptive (Norethindrone Plus Ethinyl Estradiol) in Female Patients With Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 09 Mar 2018
At a glance
- Drugs Trametinib (Primary) ; Estradiol/norethisterone
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Novartis Pharmaceuticals
- 02 Mar 2018 Planned End Date changed from 2 Jan 2019 to 14 May 2019.
- 02 Mar 2018 Planned primary completion date changed from 2 Jan 2019 to 31 Jan 2019.
- 26 Oct 2017 Planned End Date changed from 31 Dec 2018 to 2 Jan 2019.